Skip to content
Clinical Trials – home

Universita Cattolica Del Sacro Cuore

Verified siteinfo

Italy Largo Agostino Gemelli 8, 00168 Rome, Italy

  • 9 trials recruiting
  • Chronic lymphocytic leukaemia · Breast cancer · Diffuse large B-cell lymphoma
  • Adults and children

About Specializations

Universita Cattolica Del Sacro Cuore in Rome, Italy specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Breast cancer, Diffuse large B-cell lymphoma, Bladder transitional cell carcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Immune-Mediated Disease

The research program at Universita Cattolica Del Sacro Cuore includes studies in digestive system diseases and immune system diseases, with a strong focus on Crohn’s disease, lupus nephritis, and non-alcoholic steatohepatitis. These trials are designed to test new treatment options and better understand how to control inflammation and organ damage over time.

  • Inflammatory bowel disease, especially Crohn’s disease
  • Autoimmune kidney disease and systemic immune disorders
  • Chronic liver disease linked to metabolic dysfunction

Overall, this area reflects a broad effort to improve symptom control, slow disease progression, and support more effective long-term care.

Oncology and Hematologic Malignancies

A major part of the clinical trial activity centers on neoplasms and hemic and lymphatic diseases, covering cancers such as breast cancer, ovarian cancer, lung cancer, prostate cancer, bladder cancer, and several forms of lymphoma and leukemia. These studies mainly aim to evaluate new therapies, compare treatment strategies, and improve outcomes for patients with advanced or hard-to-treat disease.

  • Solid tumors including breast, lung, prostate, ovarian, gastric, and bladder cancers
  • Blood cancers such as diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin’s lymphoma, and chronic lymphocytic leukemia
  • Research focused on treatment effectiveness, survival, and disease control

This is one of the most active therapeutic areas at the site, showing a strong commitment to innovative cancer care and precision oncology.

Neurology and Rare Diseases

The site also supports trials in nervous system diseases and congenital, hereditary, and neonatal disorders, including epilepsy, spinal muscular atrophy, and rare seizure syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. These studies are focused on improving safety, long-term disease management, and quality of life for people living with complex neurological conditions.

  • Drug-resistant focal seizures and rare epilepsy syndromes
  • Spinal muscular atrophy and long-term follow-up care
  • Studies aimed at better symptom control and ongoing safety monitoring

Research in this field highlights the site’s interest in conditions where treatment options remain limited and careful follow-up is especially important.

Cardiovascular, Musculoskeletal, and Autoimmune Research

Clinical trials in cardiovascular diseases, musculoskeletal diseases, and immune-mediated disorders explore conditions such as atherosclerotic cardiovascular disease, systemic sclerosis, idiopathic inflammatory myopathy, and plaque psoriasis. The purpose of this research is to assess whether new therapies can better prevent complications, improve disease response, and reduce the burden of chronic illness.

  • Cardiovascular risk reduction and prevention of major events
  • Autoimmune and inflammatory diseases affecting the skin, muscles, and connective tissue
  • Trials evaluating clinical improvement and treatment benefit over time

At this Rome-based research site, these studies contribute to a wider precision-medicine approach that connects internal medicine, immunology, and chronic disease management.

Infectious Disease and Specialized Supportive Care

Another important research direction involves bacterial infections and mycoses, especially invasive fungal infections caused by Aspergillus species. These trials are designed to compare treatment options and improve care for serious infections in vulnerable patients.

  • Severe fungal disease and treatment response
  • Supportive research for complex, high-risk clinical settings
  • Evaluation of new approaches to infection management

This field adds an important infectious-disease dimension to the broader clinical portfolio at Universita Cattolica Del Sacro Cuore.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Agostino Gemelli 800168 RomeItaly
Recruiting now
9 trials
Conditions studied
54
Partner status
Verified site

More sites in RomeItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

38 clinical trials

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Psoriasis

Recruiting

Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:NX-5948
  • Sponsor:Nurix Therapeutics Inc.

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Endometrial cancer+5

Recruiting

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study on Radiotherapy Alone or with Obinutuzumab for Patients with Early Stage Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Safety and Efficacy of MK-1045 with Tocilizumab in Patients with CLL/SLL

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Merck Sharp & Dohme LLC

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.